Study: German Patients Have ‘Greater Satisfaction’ With MMJ Than Previous Treatments

Study: German Patients Have ‘Greater Satisfaction’ With MMJ Than Previous Treatments

It is no secret that cannabis acts as an alternative to other long-used pharmaceuticals as it relates to the control and treatment of pain and related symptoms. Numerous studies have already confirmed the effectiveness of cannabis and its compounds in relation to pain management, but a new study shows patients believe cannabis may be even more effective than traditional treatments. It is suggested that

Recent investigation Number of German patients published in journals frontiers of medicine We investigated the experiences of cannabis products from the perspectives of over 200 anonymous participants. As in many previous studies, the majority of patients reported daily pain relief and other benefits after starting cannabis therapy.

Notably, they reported “great satisfaction” with cannabis and said it was “more effective” than previous treatments.

Exploring German Prescription Cannabis for Pain

The researchers noted that part of the intention behind the study was to explore “the perspective of patients whose experiences have been underrepresented.”

Using a web-based survey of prescription cannabinoid patients conducted from May 31, 2021 to June 2022, researchers “to reduce the influence and bias of treatment providers.” The survey was conducted anonymously. Subjects were asked to complete the cannabis treatment questionnaire twice within the same session, once at the time of the survey and once during the pre-cannabis treatment period.

Participants were asked to rate their daily pain levels, along with questions about details of the cannabinoid prescription process, i.e., any problems they encountered in obtaining the medication, and were also asked about their general attitudes toward cannabis. Ta.

The most common diagnosis was chronic pain, with 72% of participants saying pain relief was the primary reason for their prescription.

Germany is currently on hold to legalize recreational cannabis, sending ripples through the global cannabis industry, but the country legalized botanical cannabis and cannabinoid therapy for prescription use in 2017. Cannabis treatment is also typically only approved if a patient does not respond to traditional options. .

Researchers also point out that: study It was found that pain was the most common reason for which cannabinoids were prescribed in Germany from 2017 to 2022.

Patients report benefits of MMJ for pain treatment and more despite access barriers

“The results of this cross-sectional study show that most outpatients surveyed receiving treatment with prescription cannabinoids in Germany subjectively experience health benefits and symptom relief associated with these treatments. “This suggests that,” the researchers said in a discussion.

The authors report that across all diagnostic and symptom groups, participants shared positive effects on physical functioning, emotional state, and quality of life. Furthermore, they are reported to have fewer problems with social roles and have less impact on their daily life due to pain symptoms. Satisfaction was assessed by perceived effectiveness, side effects, and overall satisfaction.

The researchers found that the stress-reducing effects of cannabis drugs may be an “important mediator” and that opioids “activate the kappa opioid receptor signaling pathway by stressful stimuli that produce both aversion and discomfort. “Therefore, it may have a more ambiguous effect on stress regulation.” The same goes for humans and other animal species. ”

Before cannabis therapy, participants generally held neutral to slightly positive attitudes toward cannabis, which changed to “mainly positive” during treatment.

Most problems in the prescribing process are not caused by physicians, but rather by reimbursement issues involving health insurance providers. Approximately 25% of participants with statutory health insurance reported choosing to pay out of pocket.

“This is probably due to the current legal situation in Germany. In Germany, prescribing cannabinoid medicines is a challenge for both patients and healthcare professionals, compared to what they would encounter when prescribing off-label medicines. Similarly, it is characterized by high complexity and high administrative hurdles,” the researchers said.

A “starting point” for further research

The study notes that similar studies that directly asked German patients about cannabinoid therapy are rare, with most surveys only asking doctors. These studies similarly found that pain was the main reason for cannabis prescription.

The researchers noted the risk of selection bias, in which successful treatment may have increased patients' willingness to participate in the study, apart from much of the current research being conducted in the region. There is. They also note the potential that high access barriers to cannabinoid treatments in Germany may place high expectations among many eligible patients, leading to more favorable evaluations of such treatments, among other potential limitations. It also refers to the “expectation bias.''

“Nonetheless, this observational study provides a starting point for further discussion in the context of designing cannabinoid clinical trials and formulating appropriate research questions that include patient perspectives,” the researchers wrote. I concluded.

David B.
David B. stands out as an exceptional cannabis writer, skillfully navigating the intricate world of cannabis culture and industry. His insightful and well-researched articles provide a nuanced perspective on various aspects, from the therapeutic benefits to the evolving legal landscape. David's writing reflects a deep understanding of the plant's history, its diverse strains, and the ever-changing dynamics within the cannabis community. What sets him apart is his ability to break down complex topics into digestible pieces, making the information accessible to both seasoned enthusiasts and newcomers alike. With a keen eye for detail and a passion for the subject, David B. emerges as a reliable and engaging voice in the realm of cannabis literature.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *